{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:57:51Z","timestamp":1778295471007,"version":"3.51.4"},"reference-count":77,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>Alopecia areata (AA) is a chronic, immune-mediated disorder that targets hair follicle epithelium, thereby restricting hair growth in localized patches. Although several therapies for AA have been tested, responses with traditional therapies have been limited. In recent years, numerous reports have been published of patients with AA responding to Janus kinase (JAK) inhibitors. This literature review aims to describe AA pathophysiology, explore how and why JAK inhibitors can be used for AA treatment, and review published case reports, case series, and open-label studies published to date. Pathogenesis of AA includes interactions between genetic, environmental, and immune factors and is mediated by the cytokines interferon-\u03b3 and interleukin (IL)-15. JAK inhibition resulting in hair regrowth in some cases supports that AA is associated with the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. The emergence of JAK inhibitors for AA therapy is changing the way health care providers think about and treat AA. A mixture of animal model studies and human case studies have reported the use of baricitinib (JAK 1\/2), ruxolitinib (JAK 1\/2), and tofacitinib (JAK 1\/3) for the management of AA. JAK inhibition has shown potential as an effective AA therapy when used in case studies, case series, and open-label trials. Formal clinical trials are ongoing and will yield more definitive conclusions about the safety and efficacy of JAK inhibitors.<\/jats:p>","DOI":"10.1177\/1203475418824079","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T05:55:33Z","timestamp":1548654933000},"page":"289-297","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature"],"prefix":"10.1177","volume":"23","author":[{"given":"Erika L.","family":"Crowley","sequence":"first","affiliation":[{"name":"SKiN Centre for Dermatology, Peterborough, ON, Canada"},{"name":"Trent University, Peterborough, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamone C.","family":"Fine","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology, Peterborough, ON, Canada"},{"name":"Trent University, Peterborough, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen Kwan","family":"Katipunan","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology, Peterborough, ON, Canada"},{"name":"Probity Medical Research, Waterloo, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology, Peterborough, ON, Canada"},{"name":"Probity Medical Research, Waterloo, ON, Canada"},{"name":"Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijpd.IJPD_80_17."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.014."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1992.01680150136027."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1103442."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2011.01413.x."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S53985."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13387."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.035."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000479722."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.5546\/aap.2017.eng.e404."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.103066."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1084501."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.064."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13451."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1254147."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12556."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.03.008."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1202117."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3685."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23871."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.02.015."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.009."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0622-2."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.09.008."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205847."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0728-9."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810739."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2017.05.033."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120750."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.260."},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2491."},{"issue":"7","key":"e_1_3_3_38_2","article-title":"Alopecia universalis unresponsive to treatment with tofacitinib: report of a case with a brief review of the literature","volume":"23","author":"Salman A","year":"2017","unstructured":"Salman A, Sara\u00e7 G, Ergun T. Alopecia universalis unresponsive to treatment with tofacitinib: report of a case with a brief review of the literature. Dermatol Online\u2009J. 2017;23(7).","journal-title":"Dermatol Online\u2009J"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13290."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.073."},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.12.1867."},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3772."},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1159\/000450848."},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3574-0."},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13598."},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.15570\/actaapa.2017.15."},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1159\/000445182."},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.038."},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.027."},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13060."},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776."},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13598."},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0069-z."},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2017039."},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.007."},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0001."},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418760512."},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.032."},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_21_18."},{"issue":"7","key":"e_1_3_3_62_2","first-page":"800","article-title":"Successful treatment of severe alopecia areata with oral or topical tofacitinib","volume":"17","author":"Cheng M","year":"2018","unstructured":"Cheng M, Kehl A, Worswick S, Goh C. Successful treatment of severe alopecia areata with oral or topical tofacitinib. J\u2009Drugs Dermatol. 2018;17(7):800-803.","journal-title":"J\u2009Drugs Dermatol"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.09.032."},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1466024."},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.024."},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14871."},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16014."},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-016-0051-4."},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.4445."},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417716363."},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.031."},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.043."},{"key":"e_1_3_3_73_2","unstructured":"National Institutes of Health. U.S. National Library of Medicine. Topical tofacitinib for the treatment of alopecia areata and its variants. Published June 24 2016. Accessed February 19 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02812342."},{"key":"e_1_3_3_74_2","unstructured":"National Institutes of Health. U.S. National Library of Medicine. Study to evaluate the efficacy of tofacitinib in moderate to severe alopecia areata totalis and universalis. Published November 24 2014. Accessed February 19 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02299297."},{"key":"e_1_3_3_75_2","unstructured":"National Institutes of Health. U.S. National Library of Medicine. Tofacitinib for the treatment of alopecia areata and its variants. Published December 9 2014. Accessed February 19 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02312882."},{"key":"e_1_3_3_76_2","unstructured":"National Institutes of Health. U.S. National Library of Medicine. A study with INCB018424 Phosphate cream applied topically to subjects with alopecia areata (AA). Published September 17 2015. Accessed February 19 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02553330."},{"key":"e_1_3_3_77_2","unstructured":"National Institutes of Health. U.S. National Library of Medicine. LEO 124249 ointment in the treatment of alopecia areata. Published September 28 2015. Accessed February 19 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02561585."},{"key":"e_1_3_3_78_2","unstructured":"National Institutes of Health. U.S. National Library of Medicine. Study to evaluate the efficacy and safety profile of PF-06651600 and PF-06700841 in subjects with alopecia areata. Published November 29 2016. Accessed February 19 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02974868."}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475418824079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1203475418824079","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475418824079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:54:14Z","timestamp":1777391654000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1203475418824079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1177\/1203475418824079"],"URL":"https:\/\/doi.org\/10.1177\/1203475418824079","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]}}}